share_log

Needham Maintains Buy on Cidara Therapeutics, Adjusts Price Target To $25

Benzinga ·  Apr 25 14:23

Needham analyst Joseph Stringer maintains Cidara Therapeutics (NASDAQ:CDTX) with a Buy, adjusts target to $25 from $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment